11:02 AM EDT, 03/19/2024 (MT Newswires) -- Centogene ( CNTG ) said Tuesday it will continue to give Takeda Pharmaceutical ( TAK ) access to diagnostic testing for patients with Lysosomal Storage Disorders, or LSDs, under the companies' extended agreement.

Centogene ( CNTG ) said the companies entered into the partnership to improve patient access to testing for disorders such as Fabry and Gaucher disease, and Hunter syndrome.

The company said that the agreement was originally entered into in 2015 with Shire Pharmaceuticals, which Takeda acquired in 2019.

Price: 14.44, Change: -0.13, Percent Change: -0.86